Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial
- Resource Type
- Article
- Source
- The Lancet; 20230101, Issue: Preprints
- Subject
- Language
- ISSN
- 01406736; 1474547X